Reducing the Variability of the RiboGreen® Assay
Technical Bulletins

Share

Reducing the Variability of the RiboGreen® Assay

Introduction

Ever since the approval of the Covid-19 vaccine, there has been a significant increase in interest in nucleic acid-based medications and Lipid nanoparticles (LNPs) for targeted drug delivery. With the rapid development of such systems, the development of quality characterization methods is trying to catch up and provide accurate and robust analysis techniques. Meanwhile, more traditional techniques have been deployed to help characterize some quality attributes of these drug products. One such technique is the fluorescence-based assay, RiboGreen®.

The RiboGreen® assay is a very sensitive method for evaluating the encapsulation efficiency of an LNP, but due to the multistep process required during testing, it may carry a high level of variability. This technical bulletin will provide an evaluation of the inherent variability of the assay and a comparison of data generated by two analysts and an automated system.

Want to Learn More?

Download Content

Phosphorex LLC is committed to protecting and respecting your privacy, and we'll only use your personal information to administer your account and to provide the products and services you requested from us. From time to time, we would like to contact you about our products and services, as well as other content that may be of interest to you. If you consent to us contacting you for this purpose, please tick below to say how you would like us to contact you:

You can unsubscribe from these communications at any time. For more information on how to unsubscribe, our privacy practices, and how we are committed to protecting and respecting your privacy, please review our Privacy Policy.

By clicking submit below, you consent to allow Phosphorex LLC to store and process the personal information submitted above to provide you the content requested.